‌

US Patent 9925269 Phospholipid ether analogs as cancer-targeting drug vehicles

Patent 9925269 was granted and assigned to Cellectar on March, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Cellectar

Current Assignee

Cellectar

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

99252690

Patent Inventor Names

Jamey P. Weichert0

Kevin Kozak0

Joseph Grudzinski0

Nathan Stehle0

Marc Longino0

Anatoly Pinchuk0

Benjamin Titz0

Chorom Pak0

Date of Patent

March 27, 2018

Patent Application Number

149342030

Date Filed

November 6, 2015

Patent Primary Examiner

‌

Noble E Jarrell

Patent abstract

The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9925269 Phospholipid ether analogs as cancer-targeting drug vehicles

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API